Physician-Hospital Integration Impact on Healthcare Quality and Costs

By Staff Writer

August 19, 2024

Introduction

The integration of physicians with hospitals and health systems has surged over the past decade. Between 2012 and 2022, the percentage of physicians in the US in private practice dropped from 60% to 47%, while those employed by or contracted with hospitals or health systems increased from 29% to 41%. This trend raises concerns about higher prices due to the increased negotiating power physicians gain through their affiliations. However, the impact on healthcare quality remains debated. This article examines the effects of physician-hospital integration, particularly focusing on primary care physicians (PCPs) and their access to expanded resources.

The Shift Towards Vertical Relationships

Vertical relationships between physicians and health systems can potentially enhance care coordination, reduce redundant services, and improve access to specialists. This is crucial for managing chronic diseases and preventing unnecessary hospital admissions or emergency department (ED) visits. Integrated systems may also facilitate better post-hospitalisation follow-ups and timely specialist visits.

However, empirical studies reveal mixed outcomes. Some research indicates that these relationships lead to higher spending due to increased prices. Others suggest improvements in cancer screening rates and appropriate ED use. Nevertheless, the overall impact on patient outcomes, such as readmissions or mortality, remains inconclusive.

Research Strategy and Techniques

A difference-in-differences study was conducted to assess the association between PCP-health system vertical relationships and various quality of care measures. The study compared outcomes for patients whose PCPs entered vertical relationships with large systems in 2015 or 2017 against those whose PCPs were either never or always in such relationships from 2013 to 2017. Data were sourced from the Massachusetts All-Payer Claims Database (2013-2017), focusing on commercially insured individuals.

Quality of Care Metrics

The study found no significant changes in low-value care utilisation, ambulatory care-sensitive condition (ACSC) inpatient admissions, or ACSC ED visits. However, there were small improvements in care timeliness and continuity. Specifically, outpatient follow-ups after hospitalisation did not change, but within-system follow-ups increased slightly for three years post-integration.

Practice Site Fragmentation

Vertical relationships were associated with decreased practice site fragmentation and increased within-system oncology follow-ups. While this may improve patient experiences, it also suggests patient steering, leading to higher spending due to increased prices. This aligns with previous studies showing no quality improvement but higher costs and intensive service use.

Revenue-Generating Incentives

The study highlights the influence of fee-for-service payment models on consolidation outcomes. Low-value care services remain revenue-generating, and the lack of change in these services could be attributed to unchanged financial incentives. Health systems with hospitals are not penalised for admissions or ED visits unless part of contracts discouraging avoidable utilisation. This may explain the observed patterns in within-system follow-ups and practice site fragmentation.

Implications for Policymakers

The findings suggest that vertical relationships between PCPs and health systems do not necessarily improve care quality but may increase costs. Policymakers and antitrust regulators should consider these outcomes when evaluating the benefits and drawbacks of healthcare consolidation. The potential for increased spending without corresponding quality improvements warrants careful consideration in policy decisions.

Conclusion

In Massachusetts, vertical relationships between PCPs and large health systems showed no significant impact on low-value care, hospital admissions, or ED visits for ACSCs among commercially insured individuals. While there were small reductions in care fragmentation and increases in within-system follow-ups, these changes suggest patient steering rather than quality improvements. Policymakers must weigh these findings against the demonstrated cost increases when considering healthcare consolidation strategies.

Reference url

Recent Posts

biosimilars price competition
            

Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Market Sustainability

💡 Are biosimilars the key to transforming U.S. healthcare costs?

A recent study reveals that as more biosimilars enter the market, original product prices drop significantly—by as much as 10-13% per competitor! This shift has led to astonishing savings, totaling $23.6 billion for Medicare between 2015 and 2023. However, concerns linger about the long-term sustainability of this competitive pricing environment.

Dive into the insights on how this booming market balances immediate cost reductions with potential future challenges.

#SyenzaNews #HealthEconomics #Pharmaceuticals #HealthcarePolicy

MFN drug pricing
       

MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alignment

💡 Are U.S. and global drug prices set for a revolution?

The new Most-Favored-Nation (MFN) drug pricing policy from the HHS and CMS aims to align U.S. pharmaceutical prices with those in economically comparable countries, promising significant reductions without stifling innovation. This bold move could lead to more accessible medications for Americans while reshaping global pricing strategies.

Curious about how this might impact your commercial and pricing strategy? Dive into the details!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation #DrugPricing

HTA reform analysis
         

HTA Reform Analysis: Patterns and Global Trends in Health Technology Assessment

🌍 Ever wondered how health technology assessment (HTA) reforms shape global healthcare?

Our latest article provides a comprehensive analysis of HTA reforms across 14 international agencies, highlighting the evolving roles of “catalysts,” “traditionalists,” and “observers.” Discover how international collaborations are pivotal in advancing HTA methodologies and ensuring patient involvement in assessment processes.

Jump into the intricacies of HTA reforms and optimize your health economics strategies!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.